Glucocorticoid mimetics, methods of making them,...

Details Glucocorticoid mimetics, methods of making them,... Glucocorticoid mimetics, methods of making them,...

2007-03-06

2007-03-06

Page, Thurman K. (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S305000, C564S337000, C564S366000, C564S395000, C564S396000

Reexamination Certificate

active

10446354

ABSTRACT:
A compound of Formula (IA) or Formula (IB)wherein R1, R2, R3, R4, R5, R6, R7, and R8are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

REFERENCES:
patent: 4880839 (1989-11-01), Tucker
patent: 5039691 (1991-08-01), Spagnuolo et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5948820 (1999-09-01), Fujita et al.
patent: 6323199 (2001-11-01), Lehmann et al.
patent: 6329534 (2001-12-01), Kym et al.
patent: 6380223 (2002-04-01), Dow et al.
patent: 6436986 (2002-08-01), Kym et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6583180 (2003-06-01), Link et al.
patent: 2002/0077356 (2002-06-01), Jaroch et al.
patent: 2002/0156311 (2002-10-01), Link et al.
patent: 2003/0105099 (2003-06-01), Graupe et al.
patent: 2003/0232823 (2003-12-01), Betageri et al.
patent: 2004/0010020 (2004-01-01), Kirrane, Jr. et al.
patent: 2004/0010148 (2004-01-01), Kirrane, Jr. et al.
patent: 2004/0023999 (2004-02-01), Bekkali et al.
patent: 2004/0029932 (2004-02-01), Bekkali et al.
patent: 2004/0097574 (2004-05-01), Marshall
patent: 900594 (1984-09-01), None
patent: 1017612 (1957-10-01), None
patent: 0 154 528 (1985-11-01), None
patent: 0 154 528 (1985-11-01), None
patent: 0 253 500 (1991-02-01), None
patent: 0 253 503 (1991-12-01), None
patent: 2 146 987 (1985-05-01), None
patent: 11 080131 (1999-03-01), None
patent: WO 96/19458 (1996-06-01), None
patent: WO 97/27852 (1997-08-01), None
patent: WO 98/54159 (1998-12-01), None
patent: WO 99/33786 (1999-07-01), None
patent: WO 99/41256 (1999-08-01), None
patent: WO 99/63976 (1999-12-01), None
patent: WO 00/32584 (2000-06-01), None
patent: WO 00 32584 (2000-06-01), None
patent: WO 00/66522 (2000-11-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 02/10143 (2002-02-01), None
patent: WO 02/051983 (2002-07-01), None
patent: WO 02/064550 (2002-08-01), None
Hawley's Condensed Chemical Dictionary 14th Edition.
Coghlan M. J. et al. J. Med Chem. 2001, 44, 2879-2885. (p. 2880.
Barnes N. J. Allergy Clin. Immunol. Apr. 1998;101(4 Pt 2): S460-464 (Abstract).
Plihal W. et al. Psychoneuroendocrinology, 1996vol. 21 No. 6, p. 515-523.
Bledsoe, K. R. Cell, 2002, vol. 110 p. 93-105.
Hamann, Lawrence, et al ; Discovery of a potent, Orally active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-gl-quinoline(LG121071), J. Med Chem, 1999, 42, 210-212.
Pooley, Charlotte, et al; Discovery and Preliminary SAR Studies of a Novel Nonsteroidal Progesterone Receptor Antagonist Pharmacophore, J. Med. Chem 1998, 41, 3461-3466.
Edwards, James, P. et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists; The Effect of D-Ring Substituents, J. Med. Chem 1998, 41, 303-310.
Zhi, Lin, et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem 1998, 41, 291-302.
Zhi, Lin; et al 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a Novel Class Of Nonsteroidal Progesterone Receptor Agonists: Effect of A-Ring Modification, J. Med. Chem 1999, 42, 1466-1472.
Tegley, Christopher, et al; 5-Benzylidene 1,2-Dihydrochromeno[3,4-f]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem 1998, 41, 4354-4359.
Edwards, James, P. et al; Preparation, Resolution and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists; J. Med. Chem, 1998,41, 2779-2785.
Hamann, Lawrence, et al; Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines J. Med. Chem 1998, 41, 623-639.
English Translation of WO/02/10143, Feb. 7, 2002.
Beilstein No. 7067440—J. Chem. Soc., Dalton, Trans., vol. 22, 1994, pp. 3202-3210; XP-002255049.
Barnes, P. J.; “Anti-inflammatory actions of glucocorticoids: molecular mechanisms”; clinical Science, 1998, vol. 94, pp. 557-572.
Barnes, P. J. et al; “Anti-inflammatory actions of steroids: molecular mechanisms”; Trends Pharm. Sci. 1993, 14, pp. 436-441.
Parente, L.; “The development of synthetic glucocorticoids”; Glucocorticoids, 2001, pp. 35-54.
Toogood, J. H.; “Glucocorticoids and asthma”; Glucocortiocids, 2001, pp. 161-174.
Oakley, R. H. et al; “The glucocorticoid receptor: expression, function, and regulation of glucocorticoid responsiveness”; Glucocorticoids, 2001, pp. 55-80.
Evans, R. M.; “The Steroid andThyroid Hormone Receptor Superfamily”; Science, 1988, 240, pp. 889-895.
Heck, S. et al; “A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1”; EMBO J., 1994, 17, pp. 4087-4095.
Reichardt, H. M. et al; “DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival”; Cell, 1998, 93, pp. 531-541.
Tronche, F. et al; “Genetic dissection of glucocorticoid receptor function in mice”; Curr. Opin. in Genetics and Dev. 1998, 8, pp. 532-538.
Bamberger, C. M. et al; “Molecular mechanisms of dissociative glucocorticoid activity” Eur. J. Clin. Invest., 2000, 30 (Suppl. 3), pp. 6-9.
Friedman, J. E., et al; “Phosphoenolpyruvate Carboxykinase (GTP) Gene Transcription and Hyperglycemia Are Regulated by Glucocorticoids in Genetically Obese db/db Transgenic Mice*”; J. biol. chem., 1997, 272, pp. 31475-31481.
Bekkali, Y., et al; Application entitled Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Appl. No. 10/639,131, May 23, 2003.
Kuzmich, D., et al; Application entitled Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Appl. No. 10/739,208, Dec. 12, 2003.
Cywin, C. et al; Application entitled Glucocorticoid Mimetics, Methods of making Them, Pharmaceutical Compositions and Uses Thereof, accorded U.S. Appl. No. 10/785,222, Feb. 24, 2004.
Abstract 1959:121889 CAPLUS; 53:121889; 53:21820h-i,21821a-c; “Tertiary Amines and Derivatives Thereof” Thomae GMBH, DE 1017612.

Affiliated with

Also associated with

Rating

Glucocorticoid mimetics, methods of making them,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glucocorticoid mimetics, methods of making them,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucocorticoid mimetics, methods of making them,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3737100